Atopic Dermatitis Treatment Research Study

Researchers at UNC Chapel Hill are partnering with individuals to learn more about treating different types of atopic dermatitis (eczema). Join our compensated study today!

Fast Facts

Group 1: Participants With Eczema Who Use Dupixent

Group 2: Participants With Eczema Who Have Not Used Dupixent

No known allergy to Vanicream (TM), hydrocortisone, triamcinolone, or dupilumab

Compensation Provided

Conducted in Chapel Hill, NC

Study Background

UNC Dermatology Clinical Trials Unit is seeking participants for a study researching eczema, also called atopic dermatitis.

Currently, the differences between various types of eczema are not well understood and we hope to learn what makes each type of eczema happen and what can be done to treat them.

If you decide to take part, you will receive study-related medical evaluation and compensation for completed visits. Participants 6 years and older may qualify. If you are an adult, you will also be asked to provide biopsy samples (some optional and some required), blood samples, and skin swabs, for which you will be paid.

Your participation in this study may help researchers improve treatment approaches for eczema. Further research today and join our compensated study!

NIH-funded study as a part of the Atopic Dermatitis Research Network

Additional Information

The purpose of this research study is to learn certain characteristics of the skin and how those characteristics are related to the severity of Atopic Dermatitis and the skin’s response to different treatments.

You or your child may qualify for this research study if you fall into one of the below groups and are 6 years of age or older:

  1. Participants with eczema with current use of Dupilumab (also called Dupixent): Use of Dupilumab must be for at least 4 months with a history of chronic atopic dermatitis that has been present for at least 1 year
  2. Participants with eczema with no prior use of Dupilumab (also called Dupixent): With a history of chronic eczema that has been present for at least 1 year but with no history of taking Dupilumab

If you decide to take part, you will receive a study-related medical evaluation and compensation for completed visits.

Depending on your clinical group assignment and your treatment course, you will complete up to 10 study visits. During these visits, clinical staff will ask questions about your health and medical history and any medications or therapies you’re currently using. They will also collect blood and skin samples.

You will not receive any experimental drugs or procedures as part of this study. You may receive the following standard-of-care treatments, which are all FDA-approved, depending on your clinical group and treatment course:

  • VanicreamTM Moisturizing Cream
  • Triamcinolone 0.1% ointment
  • Hydrocortisone 2.5% ointment
  • DUPIXENT® (dupilumab)

Yes, compensation is provided for your time.

There is no cost for you to participate in this study.